Sponsors (39)
The bill aims to speed and clarify FDA acceptance of alternative nonclinical methods—potentially accelerating patient access and reducing regulatory uncertainty—but does so by shortening public input and risking gaps in safety data while imposing short‑term compliance costs.
Patients with chronic conditions may get faster access to therapies because the bill clarifies that certain alternative nonclinical methods (e.g., in vitro, computational) can support drug development, potentially speeding transitions to human trials and approvals.
Hospitals, health systems, researchers, and the FDA gain clearer, more consistent regulatory definitions across CFR provisions, reducing administrative uncertainty for drug developers and sponsors.
Making the interim final rule immediately effective accelerates implementation of the statutory changes, avoiding delays from additional notice-and-comment procedures and enabling quicker adoption of the new regulatory approach.
If alternative nonclinical methods are used in place of animal data inappropriately, patients (including those with chronic conditions) could face increased safety risks from insufficient preclinical safety information before human trials or approvals.
Making the rule immediately effective reduces the public's opportunity to comment, limiting stakeholder input from patients, researchers, and industry into how the new definitions and policies will be applied.
Broad changes across multiple CFR sections could create short‑term compliance costs for sponsors and the FDA as systems, guidance, and procedures are updated to align with the new definitions.
Based on analysis of 2 sections of legislative text.
Introduced April 10, 2025 by Buddy Carter · Last progress April 10, 2025
Establishes a short title for the Act and requires the Secretary of Health and Human Services, acting through the FDA Commissioner, to publish an interim final rule within one year to update FDA regulations so they refer to “nonclinical tests, data, studies, models, and research” (and the defined term “nonclinical test”) instead of the prior wording that referenced animals or similar language. The interim final rule will be effective immediately upon publication and may include any additional regulatory edits needed for consistency. The bill also makes a minor technical redesignation in existing statutory text.